Tibet Duo Rui Pharmaceutical Co.Ltd.
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, intermediates, and raw materials in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as sodium acetate ringer's injection; and agent products, such as amoxicillin sodium and clavulan… Read more
Tibet Duo Rui Pharmaceutical Co.Ltd. (301075) - Net Assets
Latest net assets as of June 2025: CN¥696.22 Million CNY
Based on the latest financial reports, Tibet Duo Rui Pharmaceutical Co.Ltd. (301075) has net assets worth CN¥696.22 Million CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.45 Billion) and total liabilities (CN¥754.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥696.22 Million |
| % of Total Assets | 47.99% |
| Annual Growth Rate | 38.06% |
| 5-Year Change | 213.0% |
| 10-Year Change | N/A |
| Growth Volatility | 88.84 |
Tibet Duo Rui Pharmaceutical Co.Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Tibet Duo Rui Pharmaceutical Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tibet Duo Rui Pharmaceutical Co.Ltd. (2019–2024)
The table below shows the annual net assets of Tibet Duo Rui Pharmaceutical Co.Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥753.47 Million | -8.30% |
| 2023-12-31 | CN¥821.68 Million | +9.06% |
| 2022-12-31 | CN¥753.41 Million | -4.47% |
| 2021-12-31 | CN¥788.63 Million | +227.61% |
| 2020-12-31 | CN¥240.72 Million | +60.37% |
| 2019-12-31 | CN¥150.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tibet Duo Rui Pharmaceutical Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥89.38 Million | 13.21% |
| Other Components | CN¥587.35 Million | 86.79% |
| Total Equity | CN¥676.73 Million | 100.00% |
Tibet Duo Rui Pharmaceutical Co.Ltd. Competitors by Market Cap
The table below lists competitors of Tibet Duo Rui Pharmaceutical Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
X4 Pharmaceuticals Inc
NASDAQ:XFOR
|
$298.16 Million |
|
ITI Limited
NSE:ITI
|
$298.19 Million |
|
Guangzhou Echom Sci&Tech Co Ltd
SHE:002420
|
$298.21 Million |
|
Santa Cruz County Bank
OTCQX:SCZC
|
$298.23 Million |
|
LDR Turizm AS
IS:LIDER
|
$297.89 Million |
|
Ascencio (D)
BR:ASCE
|
$297.82 Million |
|
Wabash National Corporation
NYSE:WNC
|
$297.76 Million |
|
Daesang Corp
KO:001680
|
$297.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tibet Duo Rui Pharmaceutical Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 772,064,892 to 676,730,670, a change of -95,334,222 (-12.3%).
- Net loss of 62,666,665 reduced equity.
- Dividend payments of 17,076,146 reduced retained earnings.
- Other factors decreased equity by 15,591,411.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-62.67 Million | -9.26% |
| Dividends Paid | CN¥17.08 Million | -2.52% |
| Other Changes | CN¥-15.59 Million | -2.3% |
| Total Change | CN¥- | -12.35% |
Book Value vs Market Value Analysis
This analysis compares Tibet Duo Rui Pharmaceutical Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.43x to 9.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.70 | CN¥82.91 | x |
| 2020-12-31 | CN¥4.04 | CN¥82.91 | x |
| 2021-12-31 | CN¥9.91 | CN¥82.91 | x |
| 2022-12-31 | CN¥9.39 | CN¥82.91 | x |
| 2023-12-31 | CN¥9.65 | CN¥82.91 | x |
| 2024-12-31 | CN¥8.46 | CN¥82.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tibet Duo Rui Pharmaceutical Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.04%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 2.27x
- Recent ROE (-9.26%) is below the historical average (15.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 47.69% | 15.95% | 1.53x | 1.96x | CN¥56.67 Million |
| 2020 | 37.96% | 18.77% | 1.31x | 1.54x | CN¥67.75 Million |
| 2021 | 8.64% | 12.94% | 0.62x | 1.07x | CN¥-10.78 Million |
| 2022 | 2.73% | 5.11% | 0.45x | 1.20x | CN¥-54.65 Million |
| 2023 | 2.44% | 5.64% | 0.31x | 1.39x | CN¥-58.36 Million |
| 2024 | -9.26% | -26.04% | 0.16x | 2.27x | CN¥-130.34 Million |
Industry Comparison
This section compares Tibet Duo Rui Pharmaceutical Co.Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tibet Duo Rui Pharmaceutical Co.Ltd. (301075) | CN¥696.22 Million | 47.69% | 1.08x | $298.08 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |